

SRL Diagnostics unveils 'Heart Assure Test' to predict risk of cardiac event

28 September 2022 | News

High-sensitivity Troponin I is a specialized test that can help predict future cardiovascular risk

SRL Diagnostics has announced the launch of 'Heart Assure', a specialized test that can predict the risk of a cardiac event in an individual. High sensitivity Troponin I (hsTnI) is a simple blood test that can precisely predict a cardiac event/injury by providing a heart health risk score.

This cardiac-specific test measures even small amounts (picogram/ml) of Troponin I in the blood to calculate the risk of developing a cardiac event in the future. Based on the value attained in the test, the risk is reported as Low, Moderate or Elevated. Patients with moderate or elevated risk in the test should immediately consult a cardiologist for further diagnosis and workup.

Cardiac events like heart attacks are rising, even in the most productive age group. India has one of the highest burdens of cardiovascular disease (CVD) worldwide. The annual number of deaths from CVD in India was projected to rise from 2.26 (1990) million to 4.77 (2020) million. Heart disease prevalence rates in India have been estimated over the past several decades and have ranged from 1.6% to 7.4% in rural populations and from 1% to 13.2% in urban populations.

Troponin I is the only troponin isotope in the myocardium and is not expressed during any developmental stage in skeletal muscle. Troponin I is released into the bloodstream soon after the onset of symptoms of myocardial infarction or ischemic damage. It rises rapidly within 3 to 6 hours following the onset of chest pain, with peak concentrations at 16 to 24 hours, and remains elevated for days. In asymptomatic and healthy individuals, the troponin I test can be used to stratify risk and predict future cardiovascular risks.